Shares of Argenx (ARGX) after rising after Roche’s (RHHBY) Chugai Pharmaceutical announced results from its Phase III LUMINESCE study of Enspryng, an investigational treatment for generalized myasthenia gravis. Statistically significant data was observed in its primary endpoint, however the results did not reach expectations on the degree of clinical benefit, the company in a statement. Shares of Argenx, which markets Vyvgart for generalized myasthenia gravis, are up 12%, or $43.61, to $400.56 in premarket trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARGX:
- Argenx Highlights 2023 Achievements and Outlook
- Argenx price target raised to EUR 477 from EUR 465 at Morgan Stanley
- argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
- Argenx price target lowered to EUR 490 from EUR 510 at JPMorgan
- Argenx price target raised to $440 from $370 at Truist
